GlassScriptPhysician profile
Arabelle Abellard
NPI 1245729805
$4,178.72
in general payments reported to CMS, 2019-2025
16 companies · $991 in 2025
The $991 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2022: $1,391 · 2023: $956 · 2024: $690 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.63 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,102.44 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Glaxosmithkline, LLC. | $398.66 | 2022-2025 | Nucala |
| Blueprint Medicines Corporation | $335.05 | 2023-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $305.16 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $150.00 | 2019 | |
| Genzyme Corporation | $148.99 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $135.14 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.77 | 2023 | Cinryze |
| Alk-Abello, INC | $105.61 | 2022 | |
| Lilly USA, LLC | $96.04 | 2025 | |
| Kedrion Biopharma, INC. | $80.15 | 2024 | Koate, Kedrab, Gammaked |
| Amgen INC. | $54.87 | 2024 | Actimmune |
| Sumitomo Pharma America, INC. | $50.00 | 2023 | Rethymic |
| Ionis Pharmaceuticals, INC. | $49.96 | 2025 | Dawnzera |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $44.88 | 2023 | Actimmune |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arabelle Abellard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.